drug
brelovitug
Phase 3updated 6mo agoby $MIRM Mirum Pharmaceuticals, Inc.
Phase 3community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying brelovitug
- —Expanded-Access Program for the Treatment of Chronic Hepatitis D With Brelovitug
- phase3Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
- phase3A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
- phase3A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
- phase3A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
News(6)
- Mirum scores again in hepatitis D phase 3, setting the stage for brelovitug’s FDA runMirum Pharmaceuticals has kept its clinical winning streak alive in hepatitis D, meeting the primary endpoint in another late-stage trial of its antiviral monoclonal antibody brelovitug.fiercebiotech · 7d ago
- Vir's hepatitis delta combo tamps down virus as Gilead showdown loomsVir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.biospace · 7d ago
- Vir’s phase 3 hepatitis delta win fuels push to eclipse GileadVir Biotechnology’s phase 3 trial in chronic hepatitis delta has hit its primary endpoint, giving the biotech the first piece of the package it needs to file for FDA approval next year.fiercebiotech · 8d ago
- GSK, Ionis hepatitis B functional cure breaks open market for followersThe approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.biospace · 25d ago
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approvalA former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.biopharma_dive · 1mo ago
- Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, VirA phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead S…fiercebiotech · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that